ANTX
AN2 Therapeutics Inc
5.70$
+1.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| – | – | – | 0.01 | – | – | – | |
| – | – | – | -0.01 | – | – | – | |
| 1.57 | 0.32 | 0.90 | 1.92 | 2.33 | 1.36 | 0.82 | |
| 0.09 | 0.07 | 0.25 | 0.83 | 0.63 | 0.47 | 0.44 | |
| 1.66 | 0.39 | 1.15 | 2.76 | 2.95 | 1.83 | 1.26 | |
| -1.66 | -0.39 | -1.15 | -2.76 | -2.95 | -1.83 | -1.26 | |
| 0.00 | 0.00 | 0.00 | 0.03 | – | – | – | |
| -1.80 | -0.73 | -1.15 | -2.67 | -2.74 | -1.72 | -1.16 | |
| 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | – | – | |
| -1.80 | -0.73 | -1.15 | -2.70 | -2.74 | -1.72 | -1.16 | |
| -0.28 | -0.39 | -1.15 | -2.83 | 0.21 | 0.11 | -1.16 |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.